Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| R&D Expenses | $83 | $54 | $48 | $38 |
| G&A Expenses | $21 | $21 | $21 | $19 |
| SG&A Expenses | $21 | $21 | $21 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$0 |
| Operating Expenses | $104 | $76 | $69 | $57 |
| Operating Income | -$104 | -$76 | -$69 | -$57 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $4 | $2 | $0 |
| Pre-Tax Income | -$102 | -$71 | -$67 | -$57 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$102 | -$71 | -$65 | -$56 |
| % Margin | – | – | – | – |
| EPS | -1.62 | -1.37 | -1.73 | -2.39 |
| % Growth | -18.2% | 20.8% | 27.6% | – |
| EPS Diluted | -1.62 | -1.37 | -1.73 | -2.39 |
| Weighted Avg Shares Out | 63 | 52 | 38 | 24 |
| Weighted Avg Shares Out Dil | 63 | 52 | 38 | 24 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $8 | $2 | $0 |
| Interest Expense | -$6 | $3 | $0 | $0 |
| Depreciation & Amortization | $4 | $1 | $1 | $1 |
| EBITDA | -$104 | -$75 | -$66 | -$56 |
| % Margin | – | – | – | – |